Song Wei, Wang Kai, Zhong Fu-Ping, Fan You-Wen, Peng Lang, Zou Shu-Bing
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Oncotarget. 2016 Dec 6;7(49):81830-81838. doi: 10.18632/oncotarget.13244.
The platelet-to-lymphocyte ratio (PLR) is reported to be a prognostic factor in multiple malignancies. The aim of this study was to assess its prognostic value in hepatocellular carcinoma (HCC). We performed comprehensive searches of electronic databases for relevant studies. A total of eleven studies comprising 2,507 patients were included. Elevated PLR was significantly associated with poor overall survival (OS) (HR = 1.78; 95% CI = 1.36-2.34; P < 0.001) and disease-free survival (DFS)/recurrence-free survival (RFS) (HR = 1.82; 95% CI = 1.56-2.13; P < 0.001). The findings from most subgroup analyses were consistent with those from the overall analysis. In addition, a high PLR correlated with tumor size > 3 cm, TNM stage, lymph node metastasis, distant metastasis, and vascular invasion. We therefore conclude that elevated pretreatment PLR may be predicative of a poor prognosis in patients with HCC.
据报道,血小板与淋巴细胞比值(PLR)是多种恶性肿瘤的预后因素。本研究旨在评估其在肝细胞癌(HCC)中的预后价值。我们对电子数据库进行了全面检索以查找相关研究。共纳入了11项研究,涉及2507例患者。PLR升高与总体生存期(OS)较差显著相关(HR = 1.78;95%CI = 1.36 - 2.34;P < 0.001)以及无病生存期(DFS)/无复发生存期(RFS)较差显著相关(HR = 1.82;95%CI = 1.56 - 2.13;P < 0.001)。大多数亚组分析的结果与总体分析的结果一致。此外,高PLR与肿瘤大小>3 cm、TNM分期、淋巴结转移、远处转移和血管侵犯相关。因此,我们得出结论,治疗前PLR升高可能预示着HCC患者预后不良。